BI-2865 is a potent KRAS/P-gp inhibitor. It affects ERK/AKT signaling pathways, by reducing KRAS-GTP, inhibiting MDR and growth.
BI-2865 MOA:Targeting KRAS/MAPK Pathway for Pan-KRAS Targeted Therapy for Solid Tumors
BI-2865 is a potent KRAS/P-gp inhibitor. It affects ERK/AKT signaling pathways, by reducing KRAS-GTP, inhibiting MDR and growth.